MRI with mangafodipir trisodium in the detection and staging of pancreatic cancer.

Abstract

The purpose of this study was to compare prospectively computed tomography (CT) and magnetic resonance (MR) imaging before and after mangafodipir trisodium infusion for the detection and staging of focal pancreatic lesions. From November 1996 to October 1997, 43 consecutive patients suspected to have a focal pancreatic lesion were included in a phase III study. Triphasic helical CT was performed, as well as MRI at 1.5 T, as follows: axial T1-weighted (T1w) turbo spin echo (TSE), spectral presaturation with inversion recovery (SPIR) T1w TSE, T1w turbo field echo (TFE), and SPIR T2w TSE before and after mangafodipir trisodium (0.01 mmol/ml, 0.5 ml/kg) infusion. Imaging results were correlated with surgery, laparoscopy, laparoscopic ultrasound, and biopsy. Objective measurements were performed by measuring signal intensities (SIs) of lesion and parenchyma and calculating contrast indexes (CIs) and contrast-to-noise-ratios (CNRs) to assess the delineation of the tumor. SIs were correlated with four phantom standards with a known SI. Thirty-eight pancreatic adenocarcinomas were present, as well as one cystadenoma, two papillomas, and two cases of focal pancreatitis. SI measurements revealed significant increases in CIs for the lesion compared with the parenchyma in T1w TSE (69.7 vs 152.7; P = 0. 0003) and T1w TFE (107.8 vs 194.2; P = 0.0002). These series also revealed significant increases in CNRs (for T1w TSE: 9.7 vs 13.0; P = 0.0407 and for T1w TFE: 14.5 vs 26.1; P = 0.0001). In the other series, there was no significant increase. CT detected 38 lesions, MRI without mangafodipir trisodium detected 39 lesions, and MRI with mangafodipir trisodium detected 40 lesions, giving detection accuracy rates of 88%, 91%, and 93%, respectively. Staging accuracy rates for vascular ingrowth were 81%, 75%, and 81%, respectively. Overall staging accuracy rates were 57%, 54%, and 54%, respectively, mostly due to undetected small metastases in the peritoneum, omentum, or liver (< 1 cm). This study indicates that a) MRI after mangafodipir trisodium gives a better delineation of the tumor in T1w series, but b) does not significantly improve the detection rate and staging accuracy of focal pancreatic lesions over MRI without this contrast medium.

• Authors: M G Romijn, J Stoker, C H van Eijck, J M van Muiswinkel, C G Torres, J S Laméris
• Journal: Journal of magnetic resonance imaging : JMRI (J Magn Reson Imaging) Vol. 12 Issue 2 Pg. 261-8 (Aug 2000) ISSN: 1053-1807 [Print] United States
• PMID: 10931589 (Publication Type: Clinical Trial, Clinical Trial, Phase III, Comparative Study, Journal Article)

Chemical References

• Contrast Media
• Pyridoxal Phosphate
• Edetic Acid
• N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid

Topics

• Adult
• Aged
• Aged, 80 and over
• Contrast Media
• Diagnosis, Differential
• Edetic Acid (analogs & derivatives)
• Female
• Humans
• Image Processing, Computer-Assisted
• Infusions, Intravenous
• Magnetic Resonance Imaging
• Male
• Middle Aged
• Neoplasm Staging
• Pancreatic Neoplasms (diagnosis, diagnostic imaging, pathology)
• Prospective Studies
• Pyridoxal Phosphate (analogs & derivatives)
• Tomography, X-Ray Computed